Établissement d’un modèle murin de neuropathie des petites fibres à l’aide de la résinifératoxine

Executive Industry Relevance

This method enables the establishment of a validated small fiber neuropathy model in mice, supporting target validation and mechanistic de-risking in neuropathic pain drug discovery. By inducing selective degeneration of TRPV1-expressing sensory neurons, it provides a disease-relevant system for evaluating therapeutic hypotheses and assessing translational biomarker alignment. The model supports predictive confidence in early discovery by linking target engagement to functional sensory loss, informing go/no-go decisions in analgesic development programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates TRPV1-mediated pathways to validate target hypothesis in small fiber neuropathy.
• Operational Value: Enables functional target validation through measurable degeneration of intraepidermal nerve fibers.
• Predictive Value: Supports mechanistic de-risking by linking receptor activation to neuronal death and sensory loss.

Screening & Assay Development

• Scientific Value: Prepares a disease-relevant system for screening compounds that modulate TRPV1 or downstream neurodegeneration.
• Operational Value: Provides standardized, reproducible readouts via intraepidermal nerve fiber quantification.
• Assay Readiness: Enables reliable compound evaluation in a validated neuropathic pain model with quantifiable structural endpoints.

Translational & Preclinical Research

• Translational Continuity: Models human small fiber neuropathy through degeneration of peripheral sensory nerve terminals.
• Biomarker Alignment: Supports evaluation of intraepidermal nerve fiber density as a translational biomarker of target engagement.
• Risk-Adjusted Advancement: Informs preclinical go/no-go decisions based on dose-dependent sensory neuropathy induction.

Pipeline & Workflow Integration

The model fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, enabling iterative assessment of analgesic candidates in a pathophysiologically relevant context.

• Discovery Biology: Supports hypothesis testing of TRPV1’s role in neuropathic pain via controlled neuronal ablation.
• Screening: Delivers quantitative, histology-based outputs for compound screening and target modulation assessment.
• Analytics: Generates measurable structural and functional readouts (IENF loss, sensory deficits) to compare experimental conditions.
• Translational Research: Connects target modulation to preclinical continuity through sensory neuropathy phenotyping.
• Enterprise Reuse: Establishes a reusable platform for evaluating multiple analgesic targets and mechanisms in neuropathic pain.

Operational & Enterprise Impact

• Scientific Value: Enhances target validation confidence and reduces mechanistic ambiguity in neuropathic pain pathways.
• Operational Value: Delivers standardized, scalable model induction with minimal technical variability.
• Strategic Value: Improves go/no-go decision quality and reduces late-stage failure risk due to lack of target efficacy.
• Portfolio Impact: Enables risk-adjusted prioritization of analgesic candidates based on target-linked phenotypic outcomes.

Implementation Considerations

• Requires expertise in rodent handling, anesthesia, and intraperitoneal injection techniques.
• Dependent on access to purified resiniferatoxin and sterile preparation protocols.
• Necessitates histology infrastructure for intraepidermal nerve fiber staining and quantification.
• Involves ethical and safety considerations for handling ultrapotent TRPV1 agonists.
• Model applicability limited to TRPV1-mediated pathways; may not reflect all small fiber neuropathy etiologies.

Biopharma FAQs